Risk of significant cytopenias after treatment with tocilizumab in systemic juvenile arthritis patients with a history of macrophage activation syndrome

Pediatric Rheumatology

Volumn 10, Issue , 2012, Pages

  Kessler, Elizabeth A ^a   Vora, Sheetal S ^a   Verbsky, James W ^a,b  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b Children's Corporate Center   (United States)

Author keywords

Juvenile idiopathic arthritis; Macrophage activation syndrome; Tocilizumab

Indexed keywords

ABATACEPT; ADALIMUMAB; CYCLOSPORIN; ETANERCEPT; IMMUNOGLOBULIN; METHOTREXATE; PREDNISONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RILONACEPT; TOCILIZUMAB;

ADOLESCENT; ARTICLE; CASE REPORT; CHILD; CYTOPENIA; DISEASE ASSOCIATION; DRUG DOSE REDUCTION; FEMALE; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; MACROPHAGE ACTIVATION SYNDROME; MALE; NEUTROPENIA; NEUTROPHIL COUNT; PANCYTOPENIA; PRESCHOOL CHILD; PRIORITY JOURNAL; SIDE EFFECT; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT FAILURE;

EID: 84865441040     PISSN: None     EISSN: 15460096     Source Type: Journal    
DOI: 10.1186/1546-0096-10-30     Document Type: Article

References (8)

1. Ravelli A, Martini A. Juvenile idiopathic arthritis. Lancet 2007, 369:767-778. 10.1016/S0140-6736(07)60363-8, 17336654.
2. Grom A. Macrophage activation syndrome. Textbook of Pediatric Rheumatology 2011, 674-681. Saunders Elsevier, Philadelphia, Cassidy J, Petty R, Laxer R, Lindsley C, 6.
3. Yokota S, Imagawa T, Mori M, Miyamae M, Aihara Y, Takei S, Iwata N, Umebayashi H, Murata T, Miyoshi M, Tomita M, Nishimoto N, Kishimoto T. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet 2008, 371:998-1006. 10.1016/S0140-6736(08)60454-7, 18358927.
4. Woo P, Wilkinson N, Prieur A-M, Southwood T, Leone V, Livermore P, Wythe H, Thomson D, Kishimoto T. Open label phase II trial of single, ascending doses of MRA in Caucasian children with severe systemic juvenile idiopathic arthritis: proof of principle of the efficacy of IL-6 receptor blockade in this type of arthritis and demonstration of prolonged clinical improvement. Arthritis Res Ther 2005, 7:R1281-R1288. 10.1186/ar1826, 1297576, 16277681.
5. Yokota S, Miyamae T, Imagawa T, Iwata N, Katakura S, Mori M, Woo P, Nishimoto N, Yoshizaki K, Kishimoto T. Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 2005, 52:818-825. 10.1002/art.20944, 15751095.
6. et al. De Benedetti, Fabrizio, Brunner, Hermine, Ruperto, Nicola, Calvo, Inmaculada, Cuttica, Ruben, Malattia, Clara Tocilizumab in patients with systemic juvenile idiopathic arthritis: efficacy data from the placebo-controlled 12-week part of the phase 3 TENDER trial [abstract]. Arthritis Rheum 2010, 62(Suppl 10):1434. De Benedetti, Fabrizio, Brunner, Hermine, Ruperto, Nicola, Calvo, Inmaculada, Cuttica, Ruben, Malattia, Clara.
7. Behrens E, Beukelman T, Paessler M, Cron R. Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis. J Rheumatol 2007, 34:1133-1138.
8. Shimizu M, Nakagishi Y, Kasai K, Yamasaki Y, Miyoshi M, Takei S, et al. Tocilizumab masks the clinical symptoms of systemic juvenile idiopathic arthritis-associated macrophage activation syndrome: The diagnostic significance of interleukin-18 and interleukin-6. Cytokine 2012, 58:287-294. 10.1016/j.cyto.2012.02.006, 22398373.